Literature DB >> 3345177

Operation Everest II: lack of an effect of extreme altitude on visual contrast sensitivity.

J L Kobrick1, E Crohn, B Shukitt, C S Houston, J R Sutton, A Cymerman.   

Abstract

Contrast sensitivity thresholds were studied over 40 d during gradual ascent to a simulated terrestrial altitude of 25,000 ft in a decompression chamber. Only ambient pressure, and thus inspired oxygen pressure, was varied, thereby eliminating many of the confounding effects of cold, dehydration, malnutrition and exhaustion, inevitably encountered on very high mountains. Contrast sensitivity thresholds measured by the Ginsburg Vistech test showed no overall impairment as altitude increased. These results are different from those of other previously reported vision studies involving shorter exposures, lower altitudes, and lower test luminances. However, our results can be explained on the basis of the higher stimulus luminances used in our contrast sensitivity testing. Compared to the luminance levels involved in previously reported testing, our higher luminance stimuli would be less likely to be affected by hypoxia.

Entities:  

Mesh:

Year:  1988        PMID: 3345177

Source DB:  PubMed          Journal:  Aviat Space Environ Med        ISSN: 0095-6562


  4 in total

Review 1.  Neuropsychological functioning associated with high-altitude exposure.

Authors:  Javier Virués-Ortega; Gualberto Buela-Casal; Eduardo Garrido; Bernardino Alcázar
Journal:  Neuropsychol Rev       Date:  2004-12       Impact factor: 7.444

Review 2.  Effects of altitude on mood, behaviour and cognitive functioning. A review.

Authors:  M S Bahrke; B Shukitt-Hale
Journal:  Sports Med       Date:  1993-08       Impact factor: 11.136

3.  Operation Everest II.

Authors:  Peter D Wagner
Journal:  High Alt Med Biol       Date:  2010       Impact factor: 1.981

4.  Operation Everest II: resistance and susceptibility to chronic hypoxia in man.

Authors:  J T Reeves; C S Houston; J R Sutton
Journal:  J R Soc Med       Date:  1989-09       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.